Home » Stocks » UroGen Pharma

UroGen Pharma Ltd. (URGN)

Stock Price: $25.36 USD -0.14 (-0.55%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 556.27M
Revenue (ttm) 18,000
Net Income (ttm) -121.50M
Shares Out 21.94M
EPS (ttm) -5.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $25.36
Previous Close $25.50
Change ($) -0.14
Change (%) -0.55%
Day's Open 25.87
Day's Range 24.89 - 25.87
Day's Volume 147,760
52-Week Range 13.12 - 37.08

More Stats

Market Cap 556.27M
Enterprise Value 435.96M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 21.94M
Float 18.68M
EPS (basic) -5.8
EPS (diluted) -5.79
FCF / Share -4.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.69M
Short Ratio 14.77
Short % of Float 15.24%
Beta 1.70
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 30,904.12
PB Ratio 4.30
Revenue 18,000
Operating Income -125.61M
Net Income -121.50M
Free Cash Flow -89.10M
Net Cash 120.31M
Net Cash / Share 5.48
Gross Margin 100.00%
Operating Margin -697,811.11%
Profit Margin -674,972.20%
FCF Margin -494,972.22%
ROA -35.51%
ROE -62.30%
ROIC -94.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$45.43*
(79.14% upside)
Low
30.0
Current: 25.36
High
59.0
Target: 45.43
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue0.021.138.1617.53-
Revenue Growth-98.4%-86.17%-53.46%--
Gross Profit0.02-0.687.5617.50-
Operating Income-109-77.18-19.950.80-12.41
Net Income-105-75.66-20.00-1.94-12.69
Shares Outstanding20.5315.759.722.312.30
Earnings Per Share-5.12-4.80-2.14-1.91-5.88
Operating Cash Flow-71.02-37.33-9.574.19-7.18
Capital Expenditures-0.33-0.56-0.27-0.70-0.30
Free Cash Flow-71.34-37.89-9.843.49-7.48
Cash & Equivalents14810273.0021.3617.98
Net Cash / Debt14810273.0021.3617.98
Assets20210475.5523.0619.39
Liabilities22.0913.477.046.753.11
Book Value18090.0968.5216.3116.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name UroGen Pharma Ltd.
Country United States
Employees 174
CEO Elizabeth Barrett

Stock Information

Ticker Symbol URGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: URGN
IPO Date May 4, 2017

Description

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.